184 related articles for article (PubMed ID: 27714941)
1. Bevacizumab for non-small-cell lung cancer: A nested case control study of risk factors for hemoptysis.
Goto K; Endo M; Kusumoto M; Yamamoto N; Ohe Y; Shimizu A; Fukuoka M
Cancer Sci; 2016 Dec; 107(12):1837-1842. PubMed ID: 27714941
[TBL] [Abstract][Full Text] [Related]
2. Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumab.
Hellmann MD; Chaft JE; Rusch V; Ginsberg MS; Finley DJ; Kris MG; Price KA; Azzoli CG; Fury MG; Riely GJ; Krug LM; Downey RJ; Bains MS; Sima CS; Rizk N; Travis WD; Rizvi NA; Paik PK
Cancer Chemother Pharmacol; 2013 Aug; 72(2):453-61. PubMed ID: 23811982
[TBL] [Abstract][Full Text] [Related]
3. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
Otsuka K; Hata A; Takeshita J; Okuda C; Kaji R; Masago K; Fujita S; Katakami N
Cancer Chemother Pharmacol; 2015 Oct; 76(4):835-41. PubMed ID: 26349474
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab in Patients with Nonsquamous Non-Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study.
Besse B; Le Moulec S; Mazières J; Senellart H; Barlesi F; Chouaid C; Dansin E; Bérard H; Falchero L; Gervais R; Robinet G; Ruppert AM; Schott R; Léna H; Clément-Duchêne C; Quantin X; Souquet PJ; Trédaniel J; Moro-Sibilot D; Pérol M; Madroszyk AC; Soria JC
Clin Cancer Res; 2015 Apr; 21(8):1896-903. PubMed ID: 25614446
[TBL] [Abstract][Full Text] [Related]
5. An exceptional overall survival using bevacizumab beyond progression in a patient with non-small cell lung cancer.
Roviello G; Francini E; Perrella A; Laera L; Mazzei MA; Guerrini S; Petrioli R
Cancer Biol Ther; 2015; 16(12):1720-5. PubMed ID: 26418066
[TBL] [Abstract][Full Text] [Related]
6. A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC).
Raez LE; Santos ES; Webb RT; Wade J; Brito RA; Karr M; Kennah A; Childs BH
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1103-10. PubMed ID: 24057043
[TBL] [Abstract][Full Text] [Related]
7. Retrospective analysis of bevacizumab-induced hypertension and clinical outcome in patients with colorectal cancer and lung cancer.
Nakaya A; Kurata T; Yokoi T; Iwamoto S; Torii Y; Katashiba Y; Ogata M; Hamada M; Kon M; Nomura S
Cancer Med; 2016 Jul; 5(7):1381-7. PubMed ID: 27109438
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study.
Crinò L; Dansin E; Garrido P; Griesinger F; Laskin J; Pavlakis N; Stroiakovski D; Thatcher N; Tsai CM; Wu YL; Zhou C
Lancet Oncol; 2010 Aug; 11(8):733-40. PubMed ID: 20650686
[TBL] [Abstract][Full Text] [Related]
9. Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts.
Reck M; Barlesi F; Crinò L; Henschke CI; Isla D; Stiebeler S; Spigel DR
Ann Oncol; 2012 May; 23(5):1111-1120. PubMed ID: 22056855
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab as first-line treatment for advanced non-small cell lung cancer.
Socinski MA
Drugs Today (Barc); 2008 Apr; 44(4):293-301. PubMed ID: 18536787
[TBL] [Abstract][Full Text] [Related]
11. MO19390 (SAiL): bleeding events in a phase IV study of first-line bevacizumab with chemotherapy in patients with advanced non-squamous NSCLC.
Dansin E; Cinieri S; Garrido P; Griesinger F; Isla D; Koehler M; Kohlhaeufl M
Lung Cancer; 2012 Jun; 76(3):373-9. PubMed ID: 22236866
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of bevacizumab in non-squamous, non-small-cell lung cancer patients with malignant pleural effusion.
Di W; Yue C; Ziran Z; Jie Z; Jun N; Ling D; Weiheng H; Xiaoling C; Xiangjuan M; Guangming T; Jindi H; Sen H; Yang W; Jieran L; Jian F
Future Oncol; 2022 Feb; 18(6):669-677. PubMed ID: 35080187
[No Abstract] [Full Text] [Related]
13. Effectiveness of bevacizumab exposure beyond disease progression in patients with non-small-cell lung cancer: analyses of the ARIES observational cohort study.
Leon L; Kosty M; Jahanzeb M; Spigel D; Wozniak AJ; Brahmer J; Fish S; Flick ED; Hazard SJ; Lynch TJ
Pharmacoepidemiol Drug Saf; 2016 May; 25(5):569-77. PubMed ID: 26748833
[TBL] [Abstract][Full Text] [Related]
14. Stromal Caveolin-1 Is Associated With Response and Survival in a Phase II Trial of nab-Paclitaxel With Carboplatin for Advanced NSCLC Patients.
Bertino EM; Williams TM; Nana-Sinkam SP; Shilo K; Chatterjee M; Mo X; Rahmani M; Phillips GS; Villalona-Calero MA; Otterson GA
Clin Lung Cancer; 2015 Nov; 16(6):466-74. PubMed ID: 26123189
[TBL] [Abstract][Full Text] [Related]
15. AVAiLABLE NIS - AVASTIN® in lung cancer treatment in routine oncology practice in Germany.
Zahn MO; Linck D; Losem C; Gessner C; Metze H; Gaillard VE; Tessen HW
BMC Cancer; 2019 May; 19(1):433. PubMed ID: 31077164
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab safety in Japanese patients with colorectal cancer.
Hatake K; Doi T; Uetake H; Takahashi Y; Ishihara Y; Shirao K
Jpn J Clin Oncol; 2016 Mar; 46(3):234-40. PubMed ID: 26774113
[TBL] [Abstract][Full Text] [Related]
17. Switch maintenance therapy with docetaxel and bevacizumab after induction therapy with cisplatin, pemetrexed, and bevacizumab in advanced non-squamous non-small cell lung cancer: a phase II study.
Nishimoto K; Karayama M; Inui N; Yasui H; Hozumi H; Suzuki Y; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Inami N; Matsuura S; Kaida Y; Matsui T; Asada K; Matsuda H; Fujii M; Toyoshima M; Imokawa S; Suda T
Med Oncol; 2018 Jun; 35(7):108. PubMed ID: 29909581
[TBL] [Abstract][Full Text] [Related]
18. BRIDGE: an open-label phase II trial evaluating the safety of bevacizumab + carboplatin/paclitaxel as first-line treatment for patients with advanced, previously untreated, squamous non-small cell lung cancer.
Hainsworth JD; Fang L; Huang JE; Karlin D; Russell K; Faoro L; Azzoli C
J Thorac Oncol; 2011 Jan; 6(1):109-14. PubMed ID: 21107290
[TBL] [Abstract][Full Text] [Related]
19. Changes in cross-sectional area of pulmonary vessels on chest computed tomography after chemotherapy in patients with advanced non-squamous non-small-cell lung cancer.
Karayama M; Inui N; Kusagaya H; Suzuki S; Inoue Y; Enomoto N; Fujisawa T; Nakamura Y; Suda T
Cancer Chemother Pharmacol; 2016 May; 77(5):1011-8. PubMed ID: 27034279
[TBL] [Abstract][Full Text] [Related]
20. Feasibility study of docetaxel plus bevacizumab as first line therapy for elderly patients with advanced non-small-cell lung cancer: Thoracic Oncology Research Group (TORG) 1014.
Takagi Y; Hosomi Y; Oshita F; Okamoto H; Seki N; Minato K; Aono H; Yamada K; Okuma Y; Hida N; Sakamoto T; Miura Y; Yomota M; Satoh A; Kunitoh H; Sakamaki K; Shibuya M; Watanabe K
BMC Cancer; 2015 Oct; 15():740. PubMed ID: 26481215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
